Search Result
Results for "
serum level
" in MedChemExpress (MCE) Product Catalog:
3
Biochemical Assay Reagents
5
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-108288
-
|
Pivsulbactam; CP 47904
|
Beta-lactamase
Antibiotic
Bacterial
|
Infection
|
|
Sulbactam pivoxil (Pivsulbactam) is a prodrug of Sulbactam (HY-B0334) with oral activity. Sulbactam is a β-lactamase inhibitor with antibacterial activity. Sulbactam pivoxil is better absorbed than Sulbactam and results in higher serum levels after oral administration .
|
-
-
- HY-13995B
-
|
|
Others
|
Metabolic Disease
|
|
Sevelamer carbonate is an orally active and non-calcium-based phosphate binding agent and used for the hyperphosphatemia of chronic kidney disease (CKD)research. Sevelamer carbonate effectively lowers serum phosphorus levels hile having minimal effect on serum calcium or serum chloride levels in vivo. Sevelamer carbonate is considered as an improved, buffered form of sevelamer (HY-13995) .
|
-
-
- HY-W012946
-
-
-
- HY-101812
-
|
|
Others
|
Metabolic Disease
|
|
Terbufibrol has been shown highly active in reducing serum total cholesterol (TC) levels in the normal and hypercholesterolemic male rat.
|
-
-
- HY-112961
-
|
|
JAK
Interleukin Related
STAT
|
Metabolic Disease
|
|
Patiromer is an orally active, selective and non-absorbable intestinal potassium (K +) polymer binder that reversibly binds potassium ions in exchange for calcium (Ca 2+). Patiromer can rapidly and continuously reduce serum potassium levels, maintain a normal blood potassium state, and reduce serum aldosterone levels. Patiromer also increases fecal potassium excretion. Patiromer is mainly used in the study of hyperkalemia associated with diseases such as chronic kidney disease, diabetes, and heart failure, and is particularly suitable for improving renin-angiotensin-aldosterone system inhibitor (RAASi) therapy .
|
-
-
- HY-W012946S
-
-
-
- HY-W583749
-
|
|
Estrogen Receptor/ERR
|
Endocrinology
|
|
6:2 Cl-PFAES is reproductively toxic. 6:2 Cl-PFAES can cause elevated serum estradiol and vitellogenin levels in adult males and impair embryonic development in offspring .
|
-
-
- HY-P3704
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Enterostatin (rat), an orally active activation peptide of procolipase, selectively reduces fat intake. Enterostatin (rat) reduces serum cholesterol levels by way of a CCK1 receptor-dependent mechanism .
|
-
-
- HY-108288R
-
|
Pivsulbactam (Standard); CP 47904 (Standard)
|
Beta-lactamase
Reference Standards
Antibiotic
Bacterial
|
Infection
|
|
Sulbactam pivoxil (Standard) (Pivsulbactam (Standard)) is the analytical standard of Sulbactam pivoxil (HY-108288). This product is intended for research and analytical applications. Sulbactam pivoxil (Pivsulbactam) is a prodrug of Sulbactam (HY-B0334) with oral activity. Sulbactam is a β-lactamase inhibitor with antibacterial activity. Sulbactam pivoxil is better absorbed than Sulbactam and results in higher serum levels after oral administration .
|
-
-
- HY-111049
-
|
|
FXR
|
Metabolic Disease
|
|
GSK8062 is a farnesoid X receptor (FXR) agonist with activity that improves compound development parameters. Analog 1c of GSK8062 showed a reduction in weight gain and serum glucose levels .
|
-
-
- HY-W012946R
-
|
Pyromucic acid (Standard)
|
Reference Standards
ATP Citrate Lyase
Acyltransferase
Endogenous Metabolite
|
Metabolic Disease
|
|
2-Furoic acid (Standard) is the analytical standard of 2-Furoic acid. This product is intended for research and analytical applications. 2-Furoic acid (Furan-2-carboxylic acid) is an organic compound produced through furfural oxidation . 2-Furoic acid exhibits hypolipidemic effet, lowers both serum cholesterol and serum triglyceride levels in rats .
|
-
-
- HY-114316
-
-
-
- HY-145521
-
|
5(S)-Hydroxy-6E,8Z,11Z-eicosatrienoic acid
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
5(S)-HETrE is a metabolite of the ω-6 fatty acid γ-linolenic acid. 5(S)-HETrE can be elevated in serum levels in an obesity mouse model .
|
-
-
- HY-W439487
-
|
|
Nucleoside Antimetabolite/Analog
|
Metabolic Disease
|
|
7,9-Dimethylguanine is a modified nucleotide base that is a product of RNA degradation. The level of 7,9-Dimethylguanine in urine and serum can be used as a scoring indicator for the severity of alcoholic liver disease (ALD).
|
-
-
- HY-138244
-
-
-
- HY-P0056
-
|
|
GnRH Receptor
|
Cancer
|
|
Histrelin, a GnRH analogue, is a GnRH Receptor agonist. Histrelin increases serum luteinising hormone (LH), follicle stimulating hormone (FSH) and testosterone levels. Histrelin can be used in the research of prostate cancer, endometriosis .
|
-
-
- HY-P4835
-
|
|
Phosphatase
|
Others
|
|
pTH (2-34) (human) (80 μg/kg) slightly increases serum osteocalcin levels and alkaline phosphatase activity of bone extract (markers of bone formation) in mice. pTH (2-34) is not as effective as pTH (1-34) .
|
-
-
- HY-P2893B
-
|
Creatine amidinohydrolase, microorganism
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Creatine amidinohydrolase, microorganism is a hydrolytic enzyme that catalyzes the hydrolysis of creatine into creatinine and urea, playing a crucial role in the measurement of creatinine concentration. Creatine amidinohydrolase, microorganism can be used in the development of biosensors for measuring serum creatinine levels .
|
-
-
- HY-P0056A
-
|
|
GnRH Receptor
|
Cancer
|
|
Histrelin acetate, a GnRH analogue, is a GnRH Receptor agonist. Histrelin acetate increases serum luteinising hormone (LH), follicle stimulating hormone (FSH) and testosterone levels. Histrelin acetate can be used in the research of prostate cancer, endometriosis .
|
-
-
- HY-130675A
-
|
15(S)-hydroxy-Eicosapentaenoic acid; 15(S)-hydroxy EPA
|
Lipoxygenase
|
Inflammation/Immunology
|
|
15(S)-HEPE is a monohydroxy fatty acid. 15(S)-HEPE is biosynthesized from eicosapentaenoic acid by 15-lipoxygenase (15-LO). Serum levels of 15(S)-HEPE are elevated in patients with asthma.
|
-
-
- HY-149048
-
|
SAHH; AHCY
|
Endogenous Metabolite
HBV
|
Infection
Metabolic Disease
|
|
Adenosylhomocysteinase (SAHH; AHCY) is a highly conserved enzyme. Adenosylhomocysteinase reversible catalyzes S-adenosylhomocysteine (SAH) to adenosine and L-homocysteine. The serum exosomal Adenosylhomocysteinase level can be used as a prognostic biomarker in HBV-LC patients .
|
-
-
- HY-W587784
-
|
|
PPAR
|
Metabolic Disease
|
|
Norbixin is a carotenoid that has been found in B. orellana.It binds to PPARγ in a cell-free assay (Ki = 1.15 μM) . Norbixin attenuates hyperglycemia, hyperinsulinemia, and insulin resistance, as well as decreases serum lipid levels and cardiac levels of thiobarbituric acid reactive substances (TBARS) and glutathione (GSH) in a rat model of cardio-metabolic syndrome .
|
-
-
- HY-N4033
-
|
7α-Hydroxyroyleanone
|
Bacterial
|
Infection
|
|
Horminone is an abietan diterpene quinone that can be isolated from Labiatae family. Horminone increases of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) serum levels in vivo. Horminone inhibits the growth of Trypanosoma cruzi and shows antibacterial activity .
|
-
-
- HY-114952
-
|
|
Acyltransferase
|
Cardiovascular Disease
|
|
SM-32504 is an effective ACAT inhibitor that can significantly reduce serum cholesterol levels in mouse models fed with high-fat and high-cholesterol diets. SM-32504 can be used for research on hypercholesterolemia and atherosclerosis .
|
-
-
- HY-N11551
-
|
|
Others
|
Others
Metabolic Disease
|
|
Salvifaricin is an orally active diterpenoid compound that can be isolated from Salvia leucantha Cav. and Salvia hispanica L.. Salvifaricin significantly reduces fasting blood glucose and serum triglyceride (TG) levels, and has anti-diabetic effect .
|
-
-
- HY-176560
-
|
|
Others
|
Metabolic Disease
Cancer
|
|
Raloxifene alkene (Compound 101) is a serum cholesterol clearance agent. Raloxifene alkene has significant anti-proliferation activity against breast adenocarcinoma cells. Raloxifene alkene effectively reduces serum cholesterol level without significant uterine weight and increase of number oieosinoohils in the stromallaver of ovarleclomized rat models. Raloxifene alkene can be used for post-menopausasyndrome, particularly osteoporosis, estrogen-dependent breast and uterine carcinoma research .
|
-
-
- HY-W011711R
-
|
|
Reference Standards
URAT1
|
Metabolic Disease
|
|
Benzarone (Standard) is the analytical standard of Benzarone. This product is intended for research and analytical applications. Benzarone is a potent human uric acid transporter 1 (hURAT1) inhibitor, with an IC50 of 2.8 μM in oocyte. Benzarone could lower uric acid serum levels .
|
-
-
- HY-121413
-
|
|
Endogenous Metabolite
|
Others
|
|
Clinolamide is an N-cyclohexyl linoleamide. In a rat cholesterol metabolism study, feeding it at a dose of 0.3% for 21 days had no significant effect on serum, liver or kidney cholesterol levels, but had different effects on cholesterol synthesis in liver slices under different substrates and concentrations.
|
-
-
- HY-14998
-
|
MK 185
|
β-catenin
PPAR
Wnt
|
Endocrinology
|
|
Halofenate, structurally akin to clofibrate, was evaluated in hypertriglyceridemic patients over 6-week periods in a controlled, double-blind crossover trial. It effectively reduced serum triglycerides by 50%, with minimal impact on serum cholesterol levels. Additionally, it lowered serum uric acid by 30% and exhibited uricosuric effects independent of glomerular filtration rate. Halofenate was associated with a significant increase in plasma thyroxine (T4), accompanied by a decrease in protein-bound iodine and T4 by column. In vitro studies confirmed its ability to displace T4 from thyroid-binding proteins, suggesting a thyroxine-displacing effect, which could influence thyroid function in vivo .
|
-
-
- HY-W011824
-
|
|
Bacterial
Endogenous Metabolite
|
Others
|
|
2’-O-Methyluridine is a modified nucleoside that can be found in T. thermophile tRNA. 2’-O-Methyluridine can be incorporated into siRNA targeting the gene encoding apolipoprotein B, which decreases ApoB protein levels in HepG2 and prevents IFN-α production in isolated human PBMCs. 2’-O-Methyluridine level in serum is decreased in patients with breast cancer .
|
-
-
- HY-168045
-
|
|
HBV
DNA/RNA Synthesis
|
Infection
|
HBV-IN-48 is an HBV inhibitor. HBV-IN-48 has antiviral activity against HBV in HepDE19 cells, with an EC50 value of 0.005 μM. HBV-IN-48 can reduce serum HBV DNA levels in mouse models of HBV infection .
|
-
-
- HY-32351
-
Calcifediol
Maximum Cited Publications
10 Publications Verification
25-hydroxy Vitamin D3
|
VD/VDR
Endogenous Metabolite
|
Metabolic Disease
|
|
Calcifediol (25-hydroxy Vitamin D3) is an effective VDR ligand and VD supplement. Calcifediol is a prohormone of the vitamin D endocrine system (VDES) and is hydroxylated in the liver to produce the active form, calcitriol. Calcifediol can rapidly increase serum VD levels .
|
-
-
- HY-N12016
-
|
|
Others
|
Metabolic Disease
|
|
Fulvotomentoside B is a saponin isolated from Lactobacillus flavus. Fulvotomentoside compounds can significantly reduce serum glutamate pyruvate transaminase (SGPT) and triacylglycerol (GT) levels in mice poisoned by CCl4, d-galactosamine (d-gal) and acetaminophen, and significantly alleviate liver pathology. damage .
|
-
-
- HY-32351A
-
|
25-hydroxy Vitamin D3 monohydrate
|
VD/VDR
Endogenous Metabolite
|
Metabolic Disease
|
|
Calcifediol monohydrate (25-hydroxy Vitamin D3 monohydrate), is an effective VDR ligand and VD supplement. Calcifediol is a prohormone of the vitamin D endocrine system (VDES) and is hydroxylated in the liver to produce the active form, calcitriol. Calcifediol can rapidly increase serum VD levels .
|
-
-
- HY-P2446
-
|
APTAA-LHRH
|
GnRH Receptor
|
Endocrinology
|
|
ORG 30276 (APTAA-LHRH) is a potent GnRH antagonist that effectively reduces serum LH and FSH levels in male rats. ORG 30276 significantly decreases unoccupied pituitary GnRH receptors, leading to suppressed gonadotropin secretion. ORG 30276 treatment results in a considerable reduction in mRNA levels of gonadotropin beta-subunits in the pituitary gland. ORG 30276's effects on gonadotropin dynamics can be selectively reversed by the replacement of specific sex steroids, with androgens being particularly effective for the FSH beta-subunit mRNA levels.
|
-
-
- HY-109106A
-
|
SK-1403; AJT240; PLS240
|
CaSR
|
Endocrinology
|
|
Upacicalcet sodium is a non-peptide calcimimetic that acts as a CaSR agonist (EC50 = 10.8 nM). Upacicalcet sodium reduces serum intact parathyroid hormone (iPTH) and serum Ca 2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet sodium sodium improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet sodium sodium inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet sodium is useful for studying SHPT .
|
-
-
- HY-109106
-
|
SK-1403 free acid; AJT240 free acid; PLS240 free acid
|
CaSR
|
Endocrinology
|
|
Upacicalcet is a non-peptide calcimimetic that acts as a CaSR agonist (EC50 = 10.8 nM). Upacicalcet reduces serum intact parathyroid hormone (iPTH) and serum Ca2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet is useful for studying SHPT .
|
-
-
- HY-109182
-
|
JNJ-64251330
|
JAK
STAT
|
Inflammation/Immunology
|
|
Lorpucitinib (JNJ-64251330) is an orally active pan-JAK inhibitor with good enteric selectivity and safety. Lorpucitinib can inhibit the JAK/STAT pathway and reduce the levels of inflammatory biomarkers in serum. Lorpucitinib can be used in the research of familial adenomatous polyposis and gastrointestinal inflammatory diseases .
|
-
-
- HY-157917
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Nitro-PAPS disodium dihydrate is a highly sensitive colometric reagent for Fe(II) detection with a maximal absorption wavelength of 592 nm. Nitro-PAPS disodium dihydrate is suitable for the determination of Fe(II) in serum and also be used to determine micro molar levels of Cu, Zn, Ni, Co and V .
|
-
-
- HY-32351S
-
|
25-hydroxy Vitamin D3-d3
|
Isotope-Labeled Compounds
VD/VDR
Endogenous Metabolite
|
Metabolic Disease
|
|
Calcifediol-d3 is a deuterium labeled Calcifediol. Calcifediol, is an effective VDR ligand and VD supplement. Calcifediol is a prohormone of the vitamin D endocrine system (VDES) and is hydroxylated in the liver to produce the active form, calcitriol. Calcifediol can rapidly increase serum VD levels .
|
-
-
- HY-146273
-
|
|
Xanthine Oxidase
|
Metabolic Disease
|
|
Xanthine oxidase-IN-7 (compound1h) is a potent andorally active XO (xanthine oxidase) inhibitor with an IC50 of 0.36 µM. Xanthine oxidase-IN-7 effectively reduces serum uric acid levels. Xanthine oxidase-IN-7 has the potential for the research of hyperuricemia and gout .
|
-
-
- HY-P99505
-
|
COR-001; MEDI-5117; MEDI-5117; NN-6018; WBP-216
|
Interleukin Related
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Ziltivekimab (COR-001) is a humanized monoclonal antibody against IL-6 that effectively reduces serum CRP levels. Ziltivekimab possesses anti-inflammatory activity and can be used in research related to chronic systemic inflammation associated with chronic kidney disease (CKD) and cardiovascular diseases such as atherosclerosis .
|
-
-
- HY-N2638
-
|
|
Apoptosis
|
Cardiovascular Disease
|
|
Ilexsaponin A, isolated from the root of Ilex pubescens, attenuates ischemia-reperfusion-induced myocardial injury through anti-apoptotic pathway. Ilexsaponin A can reduce myocardial infarct size, lower the serum levels of LDH, AST and CK-MB, increase cellular viability and inhibit apoptosis in hypoxia/reoxygenation cardiomyocytes .
|
-
-
- HY-149429
-
|
|
PPAR
|
Metabolic Disease
|
|
PPARδ agonist 9 (compound 21) is a PPARδ agonist (EC50: 3.6 nM). PPARδ agonist 9 has in vivo efficacy, reducing serum levels of MCP-1 in mice and significantly inhibiting atherosclerosis progression in the LDLr-KO model (inhibition rate: 50-60%) .
|
-
-
- HY-N5092
-
|
|
Reactive Oxygen Species (ROS)
Cytochrome P450
|
Metabolic Disease
|
|
7-Methylcoumarin is a coumarin derivative with potent hepatoprotective and antioxidant properties. 7-Methylcoumarin is a mechanism-based inhibitor for CYP2A6. 7-Methylcoumarin significantly decreases alanine aminotransferase (ALT), aspartate aminotransferase (AST), and serum bilirubin (TB) in rats with CCl4-induced liver damage, whilst restoring total protein (TP) and albumin (TA) levels in serum as well as preventing oxidative stress. 7-Methylcoumarin can decline mitotic activity of A. sativum promeristem .
|
-
-
- HY-W679754
-
|
PFTrDA
|
TSH Receptor
|
Infection
|
|
Perfluorotridecanoic acid (PFTrDA) is a perfluoroalkyl substance (PFAS). Embryo larval exposure of PFTrDA induces yolk sac edema and increases mRNA expression of thyroid hormone synthesis genes, including tshβ, in zebrafish when used at concentrations of 0.1 and 0.3 mg/L, respectively. PFTrDA (10 mg/kg) decreases serum testosterone and luteinizing hormone levels, testis palmitic acid, linoleic acid, and oleic acid levels, and the number of Leydig cells in rats in late puberty. Maternal plasma levels of PFTrDA during gestation are positively associated with the development of eczema in female, but not male, infants, and liver levels of PFTrDA are higher in cancerous human livers compared with non-cancerous human livers. It has been found in marine mammals.
|
-
-
- HY-P990966
-
|
JR-142
|
GHR
IGF-1R
|
Others
|
|
Redalsomatropin alfa (JR-142) is a recombinant long-acting growth hormone. Redalsomatropin alfa extends its half-life through fusion with modified serum albumin. Redalsomatropin alfa is well-tolerated and can maintain IGF-1 levels. Redalsomatropin alfa can be used in research related to growth hormone deficiency .
|
-
-
- HY-P2921B
-
|
Uox, Arthrobacter globiformis
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Uricase, Arthrobacter globiformis is a peroxidase enzyme. It catalyzes the oxidation of uric acid, converting it into the soluble product allantoin. Uricase, Arthrobacter globiformis can be used for the determination of uric acid levels in serum. A deficiency of uricase in mammals can lead to kidney diseases caused by the accumulation of uric acid. Uricase, Arthrobacter globiformis can be utilized in research on gout and hyperuricemia .
|
-
-
- HY-W011711
-
|
|
URAT1
Oxidative Phosphorylation
Apoptosis
|
Metabolic Disease
|
|
Benzarone is an oral inhibitor of human urate transporter 1 (hURAT1) with an IC50 value of 2.8 μM, and it also acts as an uncoupler of oxidative phosphorylation. Benzarone can cause liver damage and promote cell apoptosis and necrosis. Benzarone can be used to lower serum uric acid levels and for research in vascular diseases .
|
-
-
- HY-P2921D
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Uricase, candida utilis is a peroxidase enzyme. It catalyzes the oxidation of uric acid, converting it into the soluble product allantoin. Uricase, candida utilis can be used for the determination of uric acid levels in serum. A deficiency of uricase in mammals can lead to kidney diseases caused by the accumulation of uric acid. Uricase, candida utilis can be utilized in research on gout and hyperuricemia .
|
-
- HY-120398
-
|
|
PTHR
|
Endocrinology
|
|
CH5447240 is an agonist for parathyroid hormone receptor 1 (PTHR1), that inhibits human PTHR1 with an EC50 of 12 μM. CH5447240 exhibits good metabolic stability in human liver microsomes. CH5447240 increases serum calcium levels in rats. CH5447240 can be used in research about hypoparathyroidism .
|
-
- HY-109106B
-
|
(Rac)-SK-1403 free acid; (Rac)-AJT240 free acid; (Rac)-PLS240 free acid
|
CaSR
|
Endocrinology
|
|
(Rac)-Upacicalcet is the racemate of Upacicalcet (HY-109106). Upacicalcet is a non-peptide calcimimetic that acts as a CaSR agonist (EC50 = 10.8 nM). Upacicalcet reduces serum intact parathyroid hormone (iPTH) and serum Ca2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet is useful for studying SHPT .
|
-
- HY-139585
-
|
LC350189
|
Xanthine Oxidase
|
Metabolic Disease
|
|
Tigulixostat (LC350189) is an orally active non-purine selective xanthine oxidase inhibitor. Tigulixostat has IC50 values of 0.003 µM and 0.073 µM in bovine milk and rat plasma, respectively. Tigulixostat can effectively reduce serum uric acid levels and can be used in the research of gout and hyperuricemia .
|
-
- HY-162622
-
|
|
Epigenetic Reader Domain
|
Inflammation/Immunology
|
|
BET-IN-26 (compound 13a) is a potent, selective and orally active BD1 inhibitor with IC50 values of 0.0055, 9.0 µM for BD1, BD2, respectively. BET-IN-26 decreases LPS (HY-D1056) induced serum levels of IL-6 and MCP-1 .
|
-
- HY-B0998
-
|
Dehydrocholate sodium
|
Amylases
Lipase
Autophagy
|
Metabolic Disease
|
|
Dehydrocholic acid (Dehydrocholate) sodium is an orally active hydrocholeretic agent. Dehydrocholic acid sodium modulates Autophagy, reduces serum amylase and lipase levels. Dehydrocholic acid sodium has the effects of promoting choleretic function, protecting the liver, reducing pancreatic damage, and regulating cholesterol metabolism. Dehydrocholic acid sodium can be used in the study of acute biliary pancreatitis and obstructive jaundice .
|
-
- HY-P2921A
-
|
Uox, Bacillus fastidious
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Uricase, Arthrobacter globiformis is a peroxidase enzyme responsible for catalyzing the oxidative reaction of uric acid, converting it into the soluble product allantoin. Uricase, Arthrobacter globiformis can be used for the determination of uric acid levels in serum. The lack of uricase in mammals can lead to kidney diseases caused by the accumulation of uric acid. Uricase, Arthrobacter globiformis can be utilized in research on gout and hyperuricemia .
|
-
- HY-32351AS
-
|
25-hydroxy Vitamin D3-d6 monohydrate
|
Isotope-Labeled Compounds
VD/VDR
Endogenous Metabolite
|
Metabolic Disease
|
|
Calcifediol-d6 monohydrate is the deuterium labeled Calcifediol monohydrate. Calcifediol monohydrate (25-hydroxy Vitamin D3 monohydrate), is an effective VDR ligand and VD supplement. Calcifediol is a prohormone of the vitamin D endocrine system (VDES) and is hydroxylated in the liver to produce the active form, calcitriol. Calcifediol can rapidly increase serum VD levels .
|
-
- HY-B1393
-
|
Dehydrocholate
|
Autophagy
Amylases
Lipase
|
Metabolic Disease
|
|
Dehydrocholic acid (Dehydrocholate) is an orally active hydrocholeretic agent. Dehydrocholic acid modulates Autophagy, reduces serum amylase and lipase levels. Dehydrocholic acid has the effects of promoting choleretic function, protecting the liver, reducing pancreatic damage, and regulating cholesterol metabolism. Dehydrocholic acid can be used in the study of acute biliary pancreatitis and obstructive jaundice .
|
-
- HY-14744A
-
|
(S)-Amlodipine besylate; Levoamlodipine besylate
|
Calcium Channel
SOD
|
Cardiovascular Disease
|
|
Levamlodipine besylate ((S)-Amlodipine besylate) is an orally active calcium channel blocker with antioxidant and vasodilatory properties. Levamlodipine besylate can reduce serum malondialdehyde (MDA) levels, increase superoxide dismutase (SOD) activity, and improve oxidative stress. Levamlodipine besylate can be used for research on vascular dementia, hypertension, and cerebrovascular diseases .
|
-
- HY-P2921C
-
|
Uox (Recombinant)
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Uricase, Arthrobacter globiformis is a peroxidase enzyme responsible for catalyzing the oxidative reaction of uric acid, converting it into the soluble product allantoin. Uricase, Arthrobacter globiformis can be used for the determination of uric acid levels in serum. The lack of uricase in mammals can lead to kidney diseases caused by the accumulation of uric acid. Uricase, Arthrobacter globiformis can be utilized in research on gout and hyperuricemia .
|
-
- HY-W679754R
-
|
PFTrDA (Standard)
|
TSH Receptor
Reference Standards
|
Infection
|
|
Pentacosafluorotridecanoic Acid (Standard) is the analytical standard of Pentacosafluorotridecanoic Acid. This product is intended for research and analytical applications. Perfluorotridecanoic acid (PFTrDA) is a perfluoroalkyl substance (PFAS). Embryo larval exposure of PFTrDA induces yolk sac edema and increases mRNA expression of thyroid hormone synthesis genes, including tshβ, in zebrafish when used at concentrations of 0.1 and 0.3 mg/L, respectively. PFTrDA (10 mg/kg) decreases serum testosterone and luteinizing hormone levels, testis palmitic acid, linoleic acid, and oleic acid levels, and the number of Leydig cells in rats in late puberty. Maternal plasma levels of PFTrDA during gestation are positively associated with the development of eczema in female, but not male, infants, and liver levels of PFTrDA are higher in cancerous human livers compared with non-cancerous human livers. It has been found in marine mammals.
|
-
- HY-32351AS1
-
|
25-Hydroxy Vitamin D3-13C5 monohydrate
|
Isotope-Labeled Compounds
VD/VDR
Endogenous Metabolite
|
Metabolic Disease
|
|
Calcifediol- 13C5 monohydrate is the 13C-labeled Calcifediol monohydrate. Calcifediol monohydrate (25-hydroxy Vitamin D3 monohydrate), is an effective VDR ligand and VD supplement. Calcifediol is a prohormone of the vitamin D endocrine system (VDES) and is hydroxylated in the liver to produce the active form, calcitriol. Calcifediol can rapidly increase serum VD levels .
|
-
- HY-32351R
-
|
25-hydroxy Vitamin D3 (Standard)
|
Reference Standards
VD/VDR
Endogenous Metabolite
|
Metabolic Disease
|
|
Calcifediol (Standard) is the analytical standard of Calcifediol. This product is intended for research and analytical applications. Calcifediol (25-hydroxy Vitamin D3) is an effective VDR ligand and VD supplement. Calcifediol is a prohormone of the vitamin D endocrine system (VDES) and is hydroxylated in the liver to produce the active form, calcitriol. Calcifediol can rapidly increase serum VD levels .
|
-
- HY-32351AR
-
|
25-hydroxy Vitamin D3 monohydrate (Standard)
|
Reference Standards
VD/VDR
Endogenous Metabolite
|
Metabolic Disease
|
|
Calcifediol monohydrate (Standard) is the analytical standard of Calcifediol (monohydrate). This product is intended for research and analytical applications. Calcifediol monohydrate (25-hydroxy Vitamin D3 monohydrate), is an effective VDR ligand and VD supplement. Calcifediol is a prohormone of the vitamin D endocrine system (VDES) and is hydroxylated in the liver to produce the active form, calcitriol. Calcifediol can rapidly increase serum VD levels .
|
-
- HY-14234
-
|
|
Glucocorticoid Receptor
|
Metabolic Disease
Inflammation/Immunology
Endocrinology
|
Glucocorticoid receptor agonist is a Glucocorticoid receptor agonist that acts on Glucocorticoid receptor (GR), progesterone receptor (PR) and mineralocorticoid receptor (MR) with the IC50 values of 2.1 , 1200 and 210 nM, respectively. Glucocorticoid receptor agonist has steroid-like anti-inflammatory properties and may be used to improve metabolism and reduce increased levels of body fat and serum insulin .
|
-
- HY-N5092R
-
|
|
Reference Standards
Reactive Oxygen Species (ROS)
Cytochrome P450
|
Metabolic Disease
|
|
7-Methylcoumarin (Standard) is the analytical standard of 7-Methylcoumarin. This product is intended for research and analytical applications. 7-Methylcoumarin is a coumarin derivative with potent hepatoprotective and antioxidant properties. 7-Methylcoumarin is a mechanism-based inhibitor for CYP2A6. 7-Methylcoumarin significantly decreases alanine aminotransferase (ALT), aspartate aminotransferase (AST), and serum bilirubin (TB) in rats with CCl4-induced liver damage, whilst restoring total protein (TP) and albumin (TA) levels in serum as well as preventing oxidative stress. 7-Methylcoumarin can decline mitotic activity of A. sativum promeristem .
|
-
- HY-P10597
-
|
|
Angiotensin Receptor
|
Others
|
|
Angiotensin II type 1 receptor (181-187) is a 9-amino acid sequence of the second extracellular loop of angiotensin II (Ang II) in the renin-angiotensin system. Angiotensin II type 1 receptor (181-187) serves as the localization epitope of angiotensin II receptor autoantibodies (AT1RaAb) and is used to detect and quantify AT1RaAb levels in serum .
|
-
- HY-N13614
-
|
|
Bacterial
IFNAR
Nuclear Factor of activated T Cells (NFAT)
NF-κB
|
Infection
Inflammation/Immunology
|
|
Centaurein, a flavonoid, is an IFN-γ promoter enhancer. Centaurein up-regulates the activity of NFAT and NF-κB enhancers. Centaurein increases the IFN-γ expression in T and NK cells and the serum IFN-γ level in mice. Centaureidin completely relaxes the contractions in intact rat aortic rings. Centaurein effectively protects mice against Listeria infection [1][2][3][4].
|
-
- HY-160552
-
|
|
Liposome
|
Others
|
|
244cis, a piperazine-containing ionizable cationic lipid, has been used to generate lipid nanoparticles (LNPs). LNPs containing 244cis and coated with mRNA reporter gene were specifically accumulated in mouse lungs compared with LNPs containing SM-102. Induces a decrease in serum chemokine (C-C motif) ligand 2 (CCL2) levels .
|
-
- HY-143294
-
|
|
Epoxide Hydrolase
|
Cardiovascular Disease
|
|
sEH inhibitor-2 (compound 5l) is an orally active (predicted percentage absorption: 71.2-88.4%) soluble epoxide hydrolase (sEH) inhibitor, with an IC50 of 0.9 nM. sEH inhibitor-2 can maintain epoxyeicosatrienoic acids (EETs) serum level in high concentrations. sEH inhibitor-2 can be used in study of cardiovascular protection .
|
-
- HY-W009081
-
|
|
Free Fatty Acid Receptor
|
Neurological Disease
|
|
Tricosanoic acid is an endogenous agonist of long-chain saturated fatty acids and free fatty acid receptor FFAR1, which can activate hair growth. Tricosanoic acid (C23:0) has the activity of improving cognitive function by regulating neuronal membrane fluidity, inhibiting neuroinflammatory response, participating in myelination and neuronal energy metabolism. Tricosanoic acid expression levels are low in the prefrontal cortex of Alzheimer's disease (AD) models; while better cognitive performance corresponds to higher serum concentration levels. Tricosanoic acid can be used as a biomarker for diseases related to cognitive decline .
|
-
- HY-B1155
-
|
Hydrocortisone 21-phosphate; Cortisol 21-phosphate
|
Phosphatase
|
Metabolic Disease
Endocrinology
|
|
Hydrocortisone phosphate (Hydrocortisone 21-phosphate) is a derivative of the glucocorticoid Hydrocortisone hemisuccinate (HY-B1402) that increases serum luteinizing hormone (LH) levels. Hydrocortisone phosphate increases the activity of magnesium-dependent polymerases in the nucleolus. Hydrocortisone phosphate also serves as a substrate for alkaline phosphatase to localize phosphatases that hydrolyze steroid phosphates, and the role of alkaline phosphatase has been validated in adult mouse tissues .
|
-
- HY-N13214
-
|
|
Others
|
Metabolic Disease
|
|
Maca Extract is a maca extract. Maca Extract has the potential to improve fertility and sexual function, and can improve non-obstructive azoospermia. The polysaccharide part is its active ingredient. Maca Extract can alleviate seminiferous tubule vacuolation and testicular lesions. It improves sperm quantity and quality by promoting the recovery of seminiferous epithelium, inhibiting stromal cell proliferation, and increasing serum testosterone levels. .
|
-
- HY-N2638R
-
|
|
Reference Standards
Apoptosis
|
Cardiovascular Disease
|
|
Ilexsaponin A (Standard) is the analytical standard of Ilexsaponin A. This product is intended for research and analytical applications. Ilexsaponin A, isolated from the root of Ilex pubescens, attenuates ischemia-reperfusion-induced myocardial injury through anti-apoptotic pathway. Ilexsaponin A can reduce myocardial infarct size, lower the serum levels of LDH, AST and CK-MB, increase cellular viability and inhibit apoptosis in hypoxia/reoxygenation cardiomyocytes .
|
-
- HY-W008581
-
|
3-O-Methyl estradiol; 17β-Estradiol 3-methyl ether; 3-Methoxyestradiol
|
Biochemical Assay Reagents
|
Endocrinology
|
|
Estradiol 3-methyl ether is a synthetic estrogen. Estradiol 3-methyl ether can disrupt microtubule networks in V79 cells with an EC50 of 9 μM, as well as inhibiting cell proliferation. Estradiol 3-methyl ether decreases the serum cholesterol levels and increases body weight loss, which indicates feminizing activity in HFD murine model .
|
-
- HY-14744C
-
|
(S)-Amlodipine hydrobromide; Levoamlodipine hydrobromide
|
Calcium Channel
SOD
|
Cardiovascular Disease
Others
|
|
Levamlodipine hydrobromide is the besylate hydrobromide salt form of Levamlodipine (HY-14744). Levamlodipine hydrobromide is an orally active calcium channel blocker with antioxidant and vasodilatory properties. Levamlodipine hydrobromide can reduce serum malondialdehyde (MDA) levels, increase superoxide dismutase (SOD) activity, and improve oxidative stress. Levamlodipine hydrobromide can be used for research on vascular dementia, hypertension, and cerebrovascular diseases .
|
-
- HY-32351B
-
|
3-epi-25-hydroxy Cholecalciferol
|
PTHR
|
Endocrinology
|
|
3-epi-25-hydroxy Vitamin D3 is the C-3 epimer of 25-hydroxy vitamin D3.1 Dietary administration of 3-epi-25-hydroxy vitamin D3 (0.5 and 1 IU/g) decreases levels of serum parathyroid hormone (PTH) in male, but not female, weanling rats.
|
-
- HY-P0037
-
|
Org 30850ANT
|
Others
GnRH Receptor
|
Endocrinology
|
|
Org-30850 is a potent LHRH antagonist designed for treating hormone-dependent disorders. In animal studies, a single subcutaneous dose effectively inhibited ovulation in rats and significantly reduced testosterone levels in male rats for up to 48 hours post-administration. Daily doses of Org-30850 in female rats suppressed estrous cycles, decreased uterine and ovarian weights, and lowered estradiol and FSH serum levels. In male rats, prolonged treatment resulted in reversible reductions in gonadal function and testosterone levels, with almost complete recovery observed after cessation of treatment. Unlike comparable LHRH antagonists, Org-30850 exhibited minimal injection site irritation and no edematous reactions, suggesting a more favorable therapeutic profile .
|
-
- HY-113777
-
|
22-Hydroxy Docosahexaenoic acid; 22-OH DHA
|
Cytochrome P450
|
Metabolic Disease
|
|
22-HDHA (22-Hydroxy Docosahexaenoic acid) is an oxidation product of docosahexaenoic acid. In vitro, it is formed upon incubation of rat liver microsomes with DHA and NADPH and also by the human cytochrome P450 (CYP) isoform CYP4F3B in BTI-TN-5B1-4 microsomes. Serum levels of 22-HDHA increase following dietary DHA supplementation in humans.
|
-
- HY-14744D
-
|
|
Calcium Channel
SOD
|
Cardiovascular Disease
Neurological Disease
|
|
Levamlodipine besylate hemipentahydrate is the besylate hemipentahydrate salt form of Levamlodipine (HY-14744). Levamlodipine besylate hemipentahydrate is an orally active calcium channel blocker with antioxidant and vasodilatory properties. Levamlodipine besylate hemipentahydrate can reduce serum malondialdehyde (MDA) levels, increase superoxide dismutase (SOD) activity, and improve oxidative stress. Levamlodipine besylate hemipentahydrate can be used for research on vascular dementia, hypertension, and cerebrovascular diseases .
|
-
- HY-105184
-
|
|
Cytochrome P450
|
Endocrinology
|
|
YM511 is a highly specific non-steroidal aromatase inhibitor. YM511 inhibits aromatase activities in microsomes from rat ovary and human placenta competitively (IC50s of 0.4 and 0.12 nM, respectively). YM511 slightly inhibits production of other steroid hormones. YM511 has the potential for suppressing estrogen-dependent action research without affecting serum levels of other steroid hormones .
|
-
- HY-N0500
-
|
|
Glycosidase
Autophagy
|
Metabolic Disease
Endocrinology
|
|
Mogroside III is a triterpenoid glycoside. Mogroside III exhibits maltase inhibitory effect with an IC50 value of 1.6 mM. Mogroside III enhances oocyte developmental potential by promoting autophagy in cumulus cells. Mogroside III, as the active ingredient of the low-polarity glycoside component (L-SGgly), L-SGgly can increase serum GLP-1 levels, improve insulin resistance, and reduce IL-6 levels, and has hypoglycemic, lipid-regulating and anti-inflammatory effects. Mogroside III can be used for the studies of type 2 diabetes mellitus (T2DM) and assisted reproductive technology .
|
-
- HY-N0407
-
|
6'-Cinnamoylcatalpol
|
STAT
|
Inflammation/Immunology
|
|
Picroside I is the major ingredient of Picrorhiza scrophulariiflora. Picrorhiza scrophulariiflora is a high value medicinal herb due to rich source of hepatoprotective metabolites, Picroside-I and Picroside-II . Picroside I is a promising agent for the management of asthma. Picroside I reduces the inflammation significantly at its higher dose. Picroside I also downregulates pSTAT6 and GATA3 expressions. Picroside I dose-dependently increases the serum levels of IFN-γ .
|
-
- HY-171904
-
|
|
Liposome
|
Others
|
|
BCP-NC2-C12 is an ionizable cationic lipid. BCP-NC2-C12 can be used to generate lipid nanoparticles (LNPs) for in vivo delivery of mRNA. BCP-NC2-C12 LNPs mediated an approximately 90% reduction in PCSK9 serum protein levels via CRISPR/Cas9 gene knockout .
|
-
- HY-114652
-
|
2-Amino-α-carboline; AαC
|
Endogenous Metabolite
|
Cancer
|
|
AalphaC (AαC) is a potential carcinogen with carcinogenic activity. AalphaC is an important biomarker in tobacco smoke and is associated with tobacco smoke exposure. Urinary concentrations of AalphaC are significantly higher in dedicated smokers than in non-smokers, indicating its importance in monitoring tobacco exposure. AalphaC levels increase significantly with increasing serum nicotine levels, indicating its close relationship with tobacco use. In addition, consuming high-temperature cooked beef significantly increases the amount of AalphaC in urine, while consuming vegetables is associated with a decrease in AalphaC concentrations. Smoking half a pack of cigarettes is associated with a significant increase in the amount of AalphaC, which further confirms the biological activity of AalphaC and its association with dietary habits .
|
-
- HY-162866
-
|
|
Autophagy
|
Metabolic Disease
|
CXM102 is an autophagy activator. CXM102 can induce autophagy in aged BMSCs, leading to the rejuvenation of BMSCs and preferential differentiation into osteoblasts. CXM102 promotes the nuclear translocation of transcription factor EB (TFEB) and the formation of osteoblasts. CXM102 can stimulate bone synthesis metabolism in middle-aged male mice, reduce bone marrow adipocytes, delay bone loss, lower serum inflammation levels, decrease organ fibrosis, and extend the lifespan of the mice .
|
-
- HY-B1393R
-
|
Dehydrocholate (Standard)
|
Reference Standards
Autophagy
Amylases
Lipase
|
Metabolic Disease
|
|
Dehydrocholic acid (Dehydrocholate) (Standard) is the analytical standard of Dehydrocholic acid (HY-B1393). This product is intended for research and analytical applications. Dehydrocholic acid (Dehydrocholate) is an orally active hydrocholeretic agent. Dehydrocholic acid modulates Autophagy, reduces serum amylase and lipase levels. Dehydrocholic acid has the effects of promoting choleretic function, protecting the liver, reducing pancreatic damage, and regulating cholesterol metabolism. Dehydrocholic acid can be used in the study of acute biliary pancreatitis and obstructive jaundice .
|
-
- HY-137307
-
|
(22S)-Hydroxycholesterol
|
LXR
ATP-binding cassette (ABC) transporters
|
Inflammation/Immunology
|
|
Cholest-5-ene-3ß,22(S)-diol ((22S)-Hydroxycholesterol) is an orally active oxysterol with no significant cytotoxic, oxidative, or inflammatory effects on human prokaryotic leukemia cells. Cholest-5-ene-3ß,22(S)-diol inhibits weight gain and increased serum triacylglycerol (TAG) levels in rat models .
|
-
- HY-176507
-
|
|
HBV
|
Infection
Inflammation/Immunology
|
|
DF-006 is a first-in-class orally active agonist of ALPK1 (α-kinase 1). DF-006 can stimulate the innate immune response by activating the NF-κB pathway and strongly stimulate the innate immunity in the liver locally. DF-006 reduces the levels of serum HBV DNA (EC50 = 2.7 pM), HBsAg and HBeAg, and has shown strong antiviral effects. DF-006 is suitable for research on the immunotherapy of chronic hepatitis B (CHB) .
|
-
- HY-174395
-
|
|
Keap1-Nrf2
Interleukin Related
Heme Oxygenase (HO)
|
Neurological Disease
|
|
CD-10 is an orally active and BBB-penatrable Keap1-Nrf2 protein-protein interaction (PPI) inhibitor. CD-10 binds to Keap1 with a KD value of 193 nM. CD-10 exhibits potent anti-oxidative and anti-inflammatory effects through Keap1-Nrf2 pathway activation, evidenced by reduced levels of MDA, IL-4, IL-10 and increased expression of HO-1. CD-10 effectively alleviated anxiety and depressive behaviors and restored serum neurotransmitter levels by promoting Nrf2 nuclear translocation in the chronic unpredictable mild stress (CUMS) mouse model. CD-10 can be used for the study of depression.
|
-
- HY-N7864
-
|
all-cis-4,7,10,13,16-Docosapentaenoic acid
|
Biochemical Assay Reagents
|
Others
|
|
Docosapentaenoic acid (DPA) is a 22-carbon fatty acid found in fish oil. It is a minor component of total serum unsaturated fatty acids in humans, ranging from 0.1% to 1%, and increasing with dietary supplementation. all-cis-4,7,10,13,16-DPA, also known as Austrian acid, is an isomer of DPA. It is an omega-6 fatty acid formed by the extension and desaturation of arachidonic acid. During fatty acid desaturase syndrome, levels of this fatty acid may be reduced, which may affect development. Upregulated hepatic elongate expression of very long fatty acid protein 6 and elevated levels of very long chain fatty acids, including all-cis 4,7,10,13,16-DPA, are characteristic of nonalcoholic steatohepatitis, a precancerous disease of hepatocellular carcinoma.
|
-
- HY-103539
-
|
|
γ-secretase
|
Metabolic Disease
|
|
3,5-Bis(4-nitrophenoxy)benzoic acid is an inhibitor of γ-secretase. 3,5-Bis(4-nitrophenoxy)benzoic acid causes a decrease in the released levels of Aβ42 and notch-1 Aβ-like peptide 25 (Nβ25). 3,5-Bis(4-nitrophenoxy)benzoic acid, as a marker for fetal hypothyroidism, is a 3,3’-diiodothyronine sulfate (T2S) cross-reactive material in maternal serum .
|
-
- HY-32351BR
-
|
3-epi-25-hydroxy Cholecalciferol (Standard)
|
PTHR
Reference Standards
|
Endocrinology
|
|
3-epi-Calcifediol (Standard) is the analytical standard of 3-epi-Calcifediol. This product is intended for research and analytical applications. 3-epi-25-hydroxy Vitamin D3 is the C-3 epimer of 25-hydroxy vitamin D3.1 Dietary administration of 3-epi-25-hydroxy vitamin D3 (0.5 and 1 IU/g) decreases levels of serum parathyroid hormone (PTH) in male, but not female, weanling rats.
|
-
- HY-N0407R
-
|
6'-Cinnamoylcatalpol (Standard)
|
Reference Standards
STAT
|
Inflammation/Immunology
|
|
Picroside I (Standard) is the analytical standard of Picroside I. This product is intended for research and analytical applications. Picroside I is the major ingredient of Picrorhiza scrophulariiflora. Picrorhiza scrophulariiflora is a high value medicinal herb due to rich source of hepatoprotective metabolites, Picroside-I and Picroside-II . Picroside I is a promising agent for the management of asthma. Picroside I reduces the inflammation significantly at its higher dose. Picroside I also downregulates pSTAT6 and GATA3 expressions. Picroside I dose-dependently increases the serum levels of IFN-γ .
|
-
- HY-147859
-
|
|
Amyloid-β
|
Neurological Disease
|
|
BChE-IN-8 (compound 20) is an orally active, potent and BBB-penetrated BChE (butyrylcholinesterase) inhibitor, with IC50 values of 0.15 nM (eqBChE, equine serum BChE) and 45.2 nM (hBChE), respectively. High stability of BChE-IN-8 contributes to significantly improved blood concentration and tissue exposure. BChE-IN-8 can exert neuro-protecting and cognition improving properties through multiple modulations, including cholinergic system, Aβ aggregation, neuropeptide levels. BChE-IN-8 can be used for Alzheimer's disease (AD) research .
|
-
- HY-N3021R
-
|
|
Endogenous Metabolite
NF-κB
TNF Receptor
FOXO
Microtubule/Tubulin
|
Metabolic Disease
|
|
D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome .
|
-
- HY-113331
-
|
|
Prostaglandin Receptor
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Thromboxane B2 is a prostaglandin derivative that is released during anaphylaxis. Thromboxane B2 induces arterial contraction and platelet aggregation. Thromboxane B2 is a biological inactive product and circulating catabolite of thromboxane A2. Thromboxane B2 levels in peripheral venous blood and coronary sinus blood can be used as a diagnostic marker for angina. Thromboxane B2 level in serum is also associated with inhibition of COX-1 activity inhibition in platelets. Thromboxane B2 is a major product of prostaglandin endoperoxide metabolism. Thromboxane B2 produces dose-related decreases in airflow rate, tidal volume and dynamic lung compliance, whilst simultaneously increasing pulmonary airway resistance in dog model. Thromboxane B2 appears to be a naturally occurring bronchoactive metabolite in the bioconversion of arachidonic acid .
|
-
- HY-W700491
-
|
2-Amino-α-carboline-15N3; AαC-15N3
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Cancer
|
|
AalphaC- 15N3 (2-Amino-α-carboline- 15N3) is 15N labeled AalphaC. AalphaC (AαC) is a potential carcinogen with carcinogenic activity. AalphaC is an important biomarker in tobacco smoke and is associated with tobacco smoke exposure. Urinary concentrations of AalphaC are significantly higher in dedicated smokers than in non-smokers, indicating its importance in monitoring tobacco exposure. AalphaC levels increase significantly with increasing serum nicotine levels, indicating its close relationship with tobacco use. In addition, consuming high-temperature cooked beef significantly increases the amount of AalphaC in urine, while consuming vegetables is associated with a decrease in AalphaC concentrations. Smoking half a pack of cigarettes is associated with a significant increase in the amount of AalphaC, which further confirms the biological activity of AalphaC and its association with dietary habits .
|
-
- HY-N3021
-
|
|
Endogenous Metabolite
NF-κB
TNF Receptor
FOXO
Microtubule/Tubulin
|
Metabolic Disease
|
|
D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome .
|
-
- HY-19522C
-
|
MBX-8025 Lysine dihydrate; RWJ-800025 Lysine dihydrate
|
PPAR
|
Metabolic Disease
|
|
Seladelpar (MBX-8025) Lysine dihydrate is the Lysine dihydrate salt form of Seladelpar (HY-19522). Seladelpar Lysine dihydrate is an orally active agonist for potent PPAR-δ, with EC50 of 2 nM. Seladelpar Lysine dihydrate shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar Lysine dihydrate can be used for the study of primary biliary cholangitis. Seladelpar Lysine dihydrate normalizes hyperglycemia, hyperinsulinemia, glucose, serum lipids and cholesterol levels, ameliorates the nonalcoholic steatohepatitis in mouse model .
|
-
- HY-139792
-
|
SHR117887
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Besigliptin tosylate (SHR117887) is a DPP-4 inhibitor with activity to improve metabolic control and β-cell function. Besigliptin tosylate can effectively reduce serum DPP-4 activity and improve oral glucose tolerance. Besigliptin tosylate significantly reduces fasting blood glucose levels and improves lipid profiles in a diabetic mouse model. The effect of besigliptin tosylate is comparable to that of the known compound vildagliptin (HY-14291) at the same concentration. Besigliptin tosylate increases insulin staining of pancreatic islet cells in chronic administration, indicating improved β-cell function .
|
-
- HY-145547
-
|
14:0 Lyso PE; 1-Myristoyl-2-hydroxy-sn-glycero-3-PE; 1-Tetradecanoyl-sn-glycero-3-phosphoethanolamine
|
Liposome
|
Metabolic Disease
|
|
1-Myristoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine (14:0 Lyso PE) is a lysophospholipid with a phosphoethanolamine head and a myristoyl tail. The free amine group can conjugate with NHS active ester or coupled with carboxylic acid in the presence of a coupling agent. It also induces transient increases in intracellular calcium in PC12 cells . Serum levels of 1-Myristoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine are elevated in patients with malignant breast cancer compared to healthy controls .
|
-
- HY-153972
-
|
|
URAT1
Xanthine Oxidase
|
Metabolic Disease
Inflammation/Immunology
|
|
URAT1&XO inhibitor 2 (Compound BDEO) is a dual inhibitor of xanthine oxidase and URAT1, with IC50 of 3.3 μM for xanthine oxidase. URAT1&XO inhibitor 2 blocks uptake of uric acid in HEK293 cells expressing URAT1, with a Ki value of 0.145 μM. URAT1&XO inhibitor 2 decreases serum urate level and uric acid excretion in hyperuricemic mice. URAT1&XO inhibitor 2 can be used for research of hyperuricemia .
|
-
- HY-P10939
-
|
|
Caspase
Pyroptosis
|
Inflammation/Immunology
Cancer
|
|
Ac-DMLD-CMK is a polypeptide targeting the mouse caspase 3-Gsdme signaling pathway. Ac-DMLD-CMK can specifically inhibit the activation of caspase 3 and Gsdme. Ac-DMLD-CMK blocks the cleavage of Gsdme by caspase 3, inhibits the occurrence of pyroptosis, thereby reducing renal tubular epithelial cell injury and the secretion of inflammatory cytokines. Ac-DMLD-CMK reduces the levels of serum creatinine and blood urea nitrogen in mice induced by Cisplatin (HY-17394) and alleviates the deterioration of kidney function. Ac-DMLD-CMK is promising for research of chemotherapy drug-induced nephrotoxicity .
|
-
- HY-159595
-
|
|
LDLR
PCSK9
|
Metabolic Disease
Inflammation/Immunology
|
PCSK9-IN-29 is a lipid-lowering agent. PCSK9-IN-29 can increase low-density lipoprotein receptor (LDLR) protein expression and decrease PCSK9 protein expression in hepG2 cells. PCSK9-IN-29 can reduce the levels of serum LDL-C, TC, and liver enzyme ALT in crab eating macaques fed a high-fat diet, lower body weight and fat, and increase bone mineral content. PCSK9-IN-29 can be used for research on non-alcoholic fatty liver disease and obesity .
|
-
- HY-176466
-
|
|
Platelet-activating Factor Receptor (PAFR)
TNF Receptor
|
Inflammation/Immunology
|
|
ST-899 is a novel platelet-activating factor (PAF) receptor antagonist. ST-899 can significantly reduce the mortality of mice with endotoxin (LPS)-induced shock. ST-899 can significantly inhibit the increase in serum tumor necrosis factor (TNF) levels induced by LPS, but has no effect on interleukin-6 (IL-6). The regulatory mechanism of ST-899 is to block the positive feedback loop between PAF and TNF, thereby reducing the inflammatory response. ST-899 can be used to study inflammatory diseases such as septic shock .
|
-
- HY-176192
-
|
|
Toll-like Receptor (TLR)
TNF Receptor
NF-κB
p38 MAPK
ERK
IKK
|
Inflammation/Immunology
|
|
SMU-14a is a TLR3 inhibitor (IC50: 0.18 µM). SMU-14a inhibits IL-6 secretion in mouse peritoneal macrophages and downregulates TNF-α in human peripheral blood monocytes. SMU-14a exerts anti-inflammatory effects by reducing the phosphorylation of p65, ERK, and TBK1 through NF-κB, MAPK, and IRF3 signaling pathways, and decreasing serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. SMU-14a can be used in the study of acute hepatitis .
|
-
- HY-134508
-
|
|
mTOR
|
Cancer
|
|
C24-Ceramide is an orally active competitive binding agonist of PIP4K2C (mTOR complex regulator), thereby activating the mTOR signaling pathway. At the same time, C24-Ceramide changes the membrane morphology by inducing the formation of a partially interlocked gel phase in the phospholipid bilayer. C24-Ceramide can promote the proliferation and migration of keratinocytes to accelerate skin wound healing and drive the proliferation and metastasis of gallbladder cancer cells. The level of C24-Ceramide in serum can be used as a diagnostic marker for gallbladder cancer .
|
-
- HY-W587488
-
|
3′-AMP
|
Nucleoside Antimetabolite/Analog
Cyclic GMP-AMP Synthase
|
Cancer
|
|
Adenosine 3’-monophosphate (3’-AMP) is a nucleotide. Adenosine 3’-monophosphate is a cyclic AMP production agonist. Adenosine 3’-monophosphate increases cyclic AMP levels concentration-dependently in NG108-15 cells. Adenosine 3’-monophosphate can be used in the determination of acid phosphatase activity of human serum, which is estabilished as a laboratory procedure in the diagnosis of prostate cancer, metastatic mammary cancer and Gaucher’s disease. Adenosine 3’-monophosphate inhibits human aortic and coronary vascular smooth muscle cell proliferation via A2B receptors .
|
-
- HY-P990797
-
|
|
IFNAR
|
Infection
Inflammation/Immunology
|
|
Anti-Mouse IFN gamma Antibody (R4-6A2) is an anti-mouse IFN gamma IgG1 monoclonal antibody. Anti-Mouse IFN gamma Antibody (R4-6A2) can increase the total serum IgG level. Anti-Mouse IFN gamma Antibody (R4-6A2) can be used for researches on immunology and infection conditions such as nymphs infection. The recommend isotype control of Anti-Mouse IFN gamma Antibody (R4-6A2): Rat IgG1 kappa, Isotype Control (HY-P99979) .
|
-
- HY-141635
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
cis-11,14-Eicosadienoic acid methyl ester is a more lipid soluble form of the ω-6 C20-2 fatty acid 11(Z),14(Z)-eicosadienoic acid, a naturally occurring PUFA. 11(Z),14(Z)-Eicosadienoic acid competitively inhibits inosine 5’-monophosphate dehydrogenase (Ki=3.1 μM) and inhibits the binding of LTB4 to its receptor on neutrophils (Ki=3.0 μM). Also, serum levels of eicosadienoic acids negatively correlate with degree of sleep disturbance.3 Eicosadienoic acids are converted by desaturases, in vivo, to eicosatrienoic acids, which are potent vasodilators.
|
-
- HY-114360
-
|
|
Endogenous Metabolite
COX
Interleukin Related
Glutathione Peroxidase
TNF Receptor
|
Metabolic Disease
Inflammation/Immunology
|
|
Taurohyodeoxycholic acid is an orally active 6 alpha-hydroxylated bile acid. Taurohyodeoxycholic acid decreases colonic MPO activity, TNF-α, lL-6 serum levels and the expression of COX-2. Taurohyodeoxycholic acid alleviates trinitrobenzene sulfonic acid induced ulcerative colitis via regulating Th1/Th2 and Th17/Treg cells balance. Taurohyodeoxycholic acid ameliorates high-fat diet-induced nonalcoholic fatty liver disease in mice. Taurohyodeoxycholic acid prevents Taurochenodeoxycholic acid (HY-N2027)-induced hepatotoxicity in bile fistula rats. Taurohyodeoxycholic acid can be used for the study of nonalcoholic fatty liver disease (NAFLD), colitis and biliary fistula .
|
-
- HY-113513
-
|
|
Others
|
Cancer
|
|
5(S)-HEPE is an active metabolite of eicosapentaenoic acid. It is formed from EPA by 5-lipoxygenase (5-LO). 5(S)-HEPE is an agonist of G protein-coupled receptor 119 (GPR119). It increases cAMP accumulation in CHO-K1 cells expressing human GPR119 when used at a concentration of 10 μM. 5(S)-HEPE increases glucose-induced insulin secretion from MING6 insulinoma pancreatic islets and glucagon-like peptide 1 (GLP-1) secretion from HuTu 80 adenocarcinoma cells when used at a concentration of 10 μM. Serum levels of 5(S)-HEPE are elevated in patients with hyperlipidemia.
|
-
- HY-N2995
-
|
Poricoic acid A(F)
|
NF-κB
Keap1-Nrf2
AMPK
TGF-beta/Smad
Reactive Oxygen Species (ROS)
|
Inflammation/Immunology
Cancer
|
|
Poricoic acid A can be isolated from Poria cocos. Poricoic acid A is an orally active anti-tumor agent. Poricoic acid A enhances melatonin inhibition of AKI-to-CKD transition by regulating Gas6/AxlNFκB/Nrf2 axis. Poricoic acid A also attenuatea fibroblast activation and abnormal extracellular matrix remodeling in renal fibrosis by activating AMPK and inhibiting Smad3. Poricoic acid A significantly reduces the magnitude of rise in serum creatinine and urea levels in rat model when combined with Melatonin. Poricoic acid A ameliorates renal fibrosis and podocyte injury by attenuating oxidative stress and inflammation through regulating NF-κB and Nrf2 in IRI rodent model in combination with Melatonin .
|
-
- HY-N15378
-
|
|
IAP
Bcl-2 Family
COX
TNF Receptor
Caspase
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
β-carotene-15,15ʹ-epoxide is a XIAP antagonist with apoptosis-inducing and antitumor activity, found in the leaves of Spondias mombin. In a DMBA (HY-W011845)-induced rat model of breast cancer, β-carotene-15,15ʹ-epoxide binds to the BIR3 domain of the anti-apoptotic protein XIAP, blocking its interaction with caspase-9 and thereby promoting tumor cell apoptosis. In addition, β-carotene-15,15ʹ-epoxide significantly downregulates the expression of BCL-2, COX-2, and TNF-α in tumor tissues, reduces MDA levels, increases catalase activity, and modulates serum levels of LDH, ALP, and ALT, demonstrating strong antioxidant, anti-inflammatory, and metabolic protective effects. β-carotene-15,15ʹ-epoxide may be used in research on inflammation-related conditions and cancers such as breast cancer .
|
-
- HY-172458
-
|
|
Mas-related G-protein-coupled Receptor (MRGPR)
TNF Receptor
|
Neurological Disease
|
|
Z-3578 is a small-molecule antagonist targeting MrgX2 (Mas-related G protein-coupled receptor X2) with significant anti-pseudoallergic activity and a KD value of 729 nM. Z-3578 effectively inhibits mast cell degranulation induced by substance P (SP) and C48/80, suppressing the release of β-hexosaminidase with IC50 values of 4.90 µM and 6.18 µM, respectively. It also markedly reduces the release of histamine and TNF-α, along with intracellular calcium flux. In a murine pseudoallergy model, Z-3578 significantly alleviates paw swelling and dye extravasation and lowers serum histamine levels, indicating potent in vivo anti-allergic effects. Z-3578 holds promise as a lead compound for the treatment of allergic diseases, especially pseudoallergic reactions .
|
-
- HY-P990818
-
|
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
|
Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) is an anti-rat FcRn heavy chain heterodimers IgG1 monoclonal antibody. Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) can effectively bind to FcRn and competitively inhibit the binding of IgG to FcRn. Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) can reduce the total serum IgG level. Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) can be used for researches on autoimmune conditions such as experimental autoimmune myasthenia gravis (EAMG). The recommend isotype control of Anti-Rat FcRn heavy chain heterodimers Antibody (1G3): Mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
- HY-138089
-
|
|
Androgen Receptor
Estrogen Receptor/ERR
LDLR
|
Metabolic Disease
Cancer
|
|
17β-Hydroxy exemestane (17-H-EXE) is the primary active metabolite of Exemestane (HY-13632). 17β-Hydroxy exemestane is an aromatase inhibitor (IC50 = 69 nM) and an androgen receptor (AR) agonist (IC50 = 39.6 nM) that is selective for AR over estrogen receptor α (ERα; IC50 = 21.2 μM). 17β-Hydroxy exemestane stimulates growth of AR- and ERα-positive MCF-7 (EC50= 2.7 μM) and T47D breast cancer cells (EC50s = 0.43 and 1500 nM for AR- and ER-mediated growth, respectively) and inhibits proliferation of testosterone-treated aromatase-overexpressing MCF-7 cells. 17β-Hydroxy exemestane inhibits increases in serum cholesterol and LDL levels and prevents decreases in bone mineral density in the lumbar vertebrae and femur, as well as femoral bending strength and compressive strength of the fifth lumbar vertebrae in ovariectomized rats .
|
-
- HY-B1904R
-
|
|
Reference Standards
Dopamine Receptor
|
Neurological Disease
|
|
Fluphenazine decanoate (Standard) is the analytical standard of Fluphenazine decanoate. This product is intended for research and analytical applications. Fluphenazine decanoate is a dopamine D2 receptor inhibitor, is a long-acting phenothiazine neuroleptic. Fluphenazine can be used for schizophrenia research .
|
-
- HY-B1904
-
|
|
Dopamine Receptor
|
Neurological Disease
|
|
Fluphenazine decanoate is a dopamine D2 receptor inhibitor, is a long-acting phenothiazine neuroleptic. Fluphenazine can be used for schizophrenia research .
|
-
- HY-B1904A
-
|
|
Dopamine Receptor
|
Neurological Disease
|
|
Fluphenazine decanoate dihydrochloride is a dopamine D2 receptor inhibitor, is a long-acting phenothiazine neuroleptic. Fluphenazine can be used for schizophrenia research .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-N7864
-
|
all-cis-4,7,10,13,16-Docosapentaenoic acid
|
Cell Assay Reagents
|
|
Docosapentaenoic acid (DPA) is a 22-carbon fatty acid found in fish oil. It is a minor component of total serum unsaturated fatty acids in humans, ranging from 0.1% to 1%, and increasing with dietary supplementation. all-cis-4,7,10,13,16-DPA, also known as Austrian acid, is an isomer of DPA. It is an omega-6 fatty acid formed by the extension and desaturation of arachidonic acid. During fatty acid desaturase syndrome, levels of this fatty acid may be reduced, which may affect development. Upregulated hepatic elongate expression of very long fatty acid protein 6 and elevated levels of very long chain fatty acids, including all-cis 4,7,10,13,16-DPA, are characteristic of nonalcoholic steatohepatitis, a precancerous disease of hepatocellular carcinoma.
|
-
- HY-134508
-
|
|
Drug Delivery
|
|
C24-Ceramide is an orally active competitive binding agonist of PIP4K2C (mTOR complex regulator), thereby activating the mTOR signaling pathway. At the same time, C24-Ceramide changes the membrane morphology by inducing the formation of a partially interlocked gel phase in the phospholipid bilayer. C24-Ceramide can promote the proliferation and migration of keratinocytes to accelerate skin wound healing and drive the proliferation and metastasis of gallbladder cancer cells. The level of C24-Ceramide in serum can be used as a diagnostic marker for gallbladder cancer .
|
-
- HY-157917
-
|
|
Chelators
|
|
Nitro-PAPS disodium dihydrate is a highly sensitive colometric reagent for Fe(II) detection with a maximal absorption wavelength of 592 nm. Nitro-PAPS disodium dihydrate is suitable for the determination of Fe(II) in serum and also be used to determine micro molar levels of Cu, Zn, Ni, Co and V .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P3704
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Enterostatin (rat), an orally active activation peptide of procolipase, selectively reduces fat intake. Enterostatin (rat) reduces serum cholesterol levels by way of a CCK1 receptor-dependent mechanism .
|
-
- HY-P0056A
-
|
|
GnRH Receptor
|
Cancer
|
|
Histrelin acetate, a GnRH analogue, is a GnRH Receptor agonist. Histrelin acetate increases serum luteinising hormone (LH), follicle stimulating hormone (FSH) and testosterone levels. Histrelin acetate can be used in the research of prostate cancer, endometriosis .
|
-
- HY-P4838
-
|
|
Peptides
|
Others
|
|
pTH (2-38) (human) is involved in the anabolic action of bone. PTH (2-38) can increase the level of serum INS-PTH (complete N-terminal specific PTH) .
|
-
- HY-P0056
-
|
|
GnRH Receptor
|
Cancer
|
|
Histrelin, a GnRH analogue, is a GnRH Receptor agonist. Histrelin increases serum luteinising hormone (LH), follicle stimulating hormone (FSH) and testosterone levels. Histrelin can be used in the research of prostate cancer, endometriosis .
|
-
- HY-P4835
-
|
|
Phosphatase
|
Others
|
|
pTH (2-34) (human) (80 μg/kg) slightly increases serum osteocalcin levels and alkaline phosphatase activity of bone extract (markers of bone formation) in mice. pTH (2-34) is not as effective as pTH (1-34) .
|
-
- HY-P2446
-
|
APTAA-LHRH
|
GnRH Receptor
|
Endocrinology
|
|
ORG 30276 (APTAA-LHRH) is a potent GnRH antagonist that effectively reduces serum LH and FSH levels in male rats. ORG 30276 significantly decreases unoccupied pituitary GnRH receptors, leading to suppressed gonadotropin secretion. ORG 30276 treatment results in a considerable reduction in mRNA levels of gonadotropin beta-subunits in the pituitary gland. ORG 30276's effects on gonadotropin dynamics can be selectively reversed by the replacement of specific sex steroids, with androgens being particularly effective for the FSH beta-subunit mRNA levels.
|
-
- HY-P10597
-
|
|
Angiotensin Receptor
|
Others
|
|
Angiotensin II type 1 receptor (181-187) is a 9-amino acid sequence of the second extracellular loop of angiotensin II (Ang II) in the renin-angiotensin system. Angiotensin II type 1 receptor (181-187) serves as the localization epitope of angiotensin II receptor autoantibodies (AT1RaAb) and is used to detect and quantify AT1RaAb levels in serum .
|
-
- HY-P0037
-
|
Org 30850ANT
|
Peptides
GnRH Receptor
|
Endocrinology
|
|
Org-30850 is a potent LHRH antagonist designed for treating hormone-dependent disorders. In animal studies, a single subcutaneous dose effectively inhibited ovulation in rats and significantly reduced testosterone levels in male rats for up to 48 hours post-administration. Daily doses of Org-30850 in female rats suppressed estrous cycles, decreased uterine and ovarian weights, and lowered estradiol and FSH serum levels. In male rats, prolonged treatment resulted in reversible reductions in gonadal function and testosterone levels, with almost complete recovery observed after cessation of treatment. Unlike comparable LHRH antagonists, Org-30850 exhibited minimal injection site irritation and no edematous reactions, suggesting a more favorable therapeutic profile .
|
-
- HY-P10939
-
|
|
Caspase
Pyroptosis
|
Inflammation/Immunology
Cancer
|
|
Ac-DMLD-CMK is a polypeptide targeting the mouse caspase 3-Gsdme signaling pathway. Ac-DMLD-CMK can specifically inhibit the activation of caspase 3 and Gsdme. Ac-DMLD-CMK blocks the cleavage of Gsdme by caspase 3, inhibits the occurrence of pyroptosis, thereby reducing renal tubular epithelial cell injury and the secretion of inflammatory cytokines. Ac-DMLD-CMK reduces the levels of serum creatinine and blood urea nitrogen in mice induced by Cisplatin (HY-17394) and alleviates the deterioration of kidney function. Ac-DMLD-CMK is promising for research of chemotherapy drug-induced nephrotoxicity .
|
-
- HY-K0319
-
3 Publications Verification
|
|
MCE Lipid Peroxidation (MDA) Assay Kit is suitable for measuring MDA levels in a variety of samples including plasma, serum, urine, tissues or cell lysates.
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99505
-
|
COR-001; MEDI-5117; MEDI-5117; NN-6018; WBP-216
|
Interleukin Related
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Ziltivekimab (COR-001) is a humanized monoclonal antibody against IL-6 that effectively reduces serum CRP levels. Ziltivekimab possesses anti-inflammatory activity and can be used in research related to chronic systemic inflammation associated with chronic kidney disease (CKD) and cardiovascular diseases such as atherosclerosis .
|
-
- HY-P9939
-
|
KRN23
|
Inhibitory Antibodies
|
Metabolic Disease
Cancer
|
|
Burosumab (KRN23) is a humanized FGF23-neutralizing antibody. By neutralizing FGF23, Burosumab blocks its inhibitory effect on renal phosphate reabsorption, thereby increasing serum phosphate levels and improving abnormal bone mineralization. Burosumab can be used in the research of diseases such as X-linked hypophosphatemia (XLH) and osteomalacia .
|
-
- HY-P990818
-
|
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
|
Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) is an anti-rat FcRn heavy chain heterodimers IgG1 monoclonal antibody. Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) can effectively bind to FcRn and competitively inhibit the binding of IgG to FcRn. Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) can reduce the total serum IgG level. Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) can be used for researches on autoimmune conditions such as experimental autoimmune myasthenia gravis (EAMG). The recommend isotype control of Anti-Rat FcRn heavy chain heterodimers Antibody (1G3): Mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
- HY-P990966
-
|
JR-142
|
GHR
IGF-1R
|
Others
|
|
Redalsomatropin alfa (JR-142) is a recombinant long-acting growth hormone. Redalsomatropin alfa extends its half-life through fusion with modified serum albumin. Redalsomatropin alfa is well-tolerated and can maintain IGF-1 levels. Redalsomatropin alfa can be used in research related to growth hormone deficiency .
|
-
- HY-P990797
-
|
|
IFNAR
|
Infection
Inflammation/Immunology
|
|
Anti-Mouse IFN gamma Antibody (R4-6A2) is an anti-mouse IFN gamma IgG1 monoclonal antibody. Anti-Mouse IFN gamma Antibody (R4-6A2) can increase the total serum IgG level. Anti-Mouse IFN gamma Antibody (R4-6A2) can be used for researches on immunology and infection conditions such as nymphs infection. The recommend isotype control of Anti-Mouse IFN gamma Antibody (R4-6A2): Rat IgG1 kappa, Isotype Control (HY-P99979) .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-W012946
-
-
-
- HY-149048
-
-
-
- HY-W587784
-
-
-
- HY-32351
-
-
-
- HY-32351A
-
-
-
- HY-N2638
-
-
-
- HY-W012946R
-
-
-
- HY-N4033
-
-
-
- HY-N11551
-
-
-
- HY-N12016
-
-
-
- HY-N5092
-
-
-
- HY-B0998
-
-
-
- HY-B1393
-
|
Dehydrocholate
|
Source classification
|
Autophagy
Amylases
Lipase
|
|
Dehydrocholic acid (Dehydrocholate) is an orally active hydrocholeretic agent. Dehydrocholic acid modulates Autophagy, reduces serum amylase and lipase levels. Dehydrocholic acid has the effects of promoting choleretic function, protecting the liver, reducing pancreatic damage, and regulating cholesterol metabolism. Dehydrocholic acid can be used in the study of acute biliary pancreatitis and obstructive jaundice .
|
-
-
- HY-32351R
-
-
-
- HY-32351AR
-
-
-
- HY-N5092R
-
|
|
Microorganisms
Source classification
Coumarins
Phenylpropanoids
|
Reference Standards
Reactive Oxygen Species (ROS)
Cytochrome P450
|
|
7-Methylcoumarin (Standard) is the analytical standard of 7-Methylcoumarin. This product is intended for research and analytical applications. 7-Methylcoumarin is a coumarin derivative with potent hepatoprotective and antioxidant properties. 7-Methylcoumarin is a mechanism-based inhibitor for CYP2A6. 7-Methylcoumarin significantly decreases alanine aminotransferase (ALT), aspartate aminotransferase (AST), and serum bilirubin (TB) in rats with CCl4-induced liver damage, whilst restoring total protein (TP) and albumin (TA) levels in serum as well as preventing oxidative stress. 7-Methylcoumarin can decline mitotic activity of A. sativum promeristem .
|
-
-
- HY-N13614
-
-
-
- HY-W009081
-
-
-
- HY-N2638R
-
-
-
- HY-N0500
-
-
-
- HY-N0407
-
-
-
- HY-N0407R
-
|
6'-Cinnamoylcatalpol (Standard)
|
Structural Classification
Iridoids
Terpenoids
Source classification
Scrophulariaceae
Plants
Picrorhiza scrophulariiflora Pennell
|
Reference Standards
STAT
|
|
Picroside I (Standard) is the analytical standard of Picroside I. This product is intended for research and analytical applications. Picroside I is the major ingredient of Picrorhiza scrophulariiflora. Picrorhiza scrophulariiflora is a high value medicinal herb due to rich source of hepatoprotective metabolites, Picroside-I and Picroside-II . Picroside I is a promising agent for the management of asthma. Picroside I reduces the inflammation significantly at its higher dose. Picroside I also downregulates pSTAT6 and GATA3 expressions. Picroside I dose-dependently increases the serum levels of IFN-γ .
|
-
-
- HY-N3021R
-
|
|
Structural Classification
Natural Products
Source classification
Endogenous metabolite
|
Endogenous Metabolite
NF-κB
TNF Receptor
FOXO
Microtubule/Tubulin
|
|
D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome .
|
-
-
- HY-N3021
-
|
|
Structural Classification
Natural Products
Classification of Application Fields
Source classification
Metabolic Disease
Endogenous metabolite
Disease Research Fields
|
Endogenous Metabolite
NF-κB
TNF Receptor
FOXO
Microtubule/Tubulin
|
|
D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome .
|
-
-
- HY-114360
-
-
-
- HY-113513
-
|
|
Microorganisms
Source classification
|
Others
|
|
5(S)-HEPE is an active metabolite of eicosapentaenoic acid. It is formed from EPA by 5-lipoxygenase (5-LO). 5(S)-HEPE is an agonist of G protein-coupled receptor 119 (GPR119). It increases cAMP accumulation in CHO-K1 cells expressing human GPR119 when used at a concentration of 10 μM. 5(S)-HEPE increases glucose-induced insulin secretion from MING6 insulinoma pancreatic islets and glucagon-like peptide 1 (GLP-1) secretion from HuTu 80 adenocarcinoma cells when used at a concentration of 10 μM. Serum levels of 5(S)-HEPE are elevated in patients with hyperlipidemia.
|
-
-
- HY-N2995
-
-
-
- HY-N15378
-
|
|
Structural Classification
Natural Products
Source classification
Spondias mombin L.
Plants
Anacardiaceae
|
IAP
Bcl-2 Family
COX
TNF Receptor
Caspase
Apoptosis
|
|
β-carotene-15,15ʹ-epoxide is a XIAP antagonist with apoptosis-inducing and antitumor activity, found in the leaves of Spondias mombin. In a DMBA (HY-W011845)-induced rat model of breast cancer, β-carotene-15,15ʹ-epoxide binds to the BIR3 domain of the anti-apoptotic protein XIAP, blocking its interaction with caspase-9 and thereby promoting tumor cell apoptosis. In addition, β-carotene-15,15ʹ-epoxide significantly downregulates the expression of BCL-2, COX-2, and TNF-α in tumor tissues, reduces MDA levels, increases catalase activity, and modulates serum levels of LDH, ALP, and ALT, demonstrating strong antioxidant, anti-inflammatory, and metabolic protective effects. β-carotene-15,15ʹ-epoxide may be used in research on inflammation-related conditions and cancers such as breast cancer .
|
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-W012946S
-
|
|
|
2-Furoic acid-d3 is the deuterium labeled 2-Furoic acid . 2-Furoic acid (Furan-2-carboxylic acid) is an organic compound produced through furfural oxidation . 2-Furoic acid exhibits hypolipidemic effet, lowers both serum cholesterol and serum triglyceride levels in rats .
|
-
-
- HY-32351S
-
|
|
|
Calcifediol-d3 is a deuterium labeled Calcifediol. Calcifediol, is an effective VDR ligand and VD supplement. Calcifediol is a prohormone of the vitamin D endocrine system (VDES) and is hydroxylated in the liver to produce the active form, calcitriol. Calcifediol can rapidly increase serum VD levels .
|
-
-
- HY-32351AS
-
|
|
|
Calcifediol-d6 monohydrate is the deuterium labeled Calcifediol monohydrate. Calcifediol monohydrate (25-hydroxy Vitamin D3 monohydrate), is an effective VDR ligand and VD supplement. Calcifediol is a prohormone of the vitamin D endocrine system (VDES) and is hydroxylated in the liver to produce the active form, calcitriol. Calcifediol can rapidly increase serum VD levels .
|
-
-
- HY-32351AS1
-
|
|
|
Calcifediol- 13C5 monohydrate is the 13C-labeled Calcifediol monohydrate. Calcifediol monohydrate (25-hydroxy Vitamin D3 monohydrate), is an effective VDR ligand and VD supplement. Calcifediol is a prohormone of the vitamin D endocrine system (VDES) and is hydroxylated in the liver to produce the active form, calcitriol. Calcifediol can rapidly increase serum VD levels .
|
-
-
- HY-W700491
-
|
|
|
AalphaC- 15N3 (2-Amino-α-carboline- 15N3) is 15N labeled AalphaC. AalphaC (AαC) is a potential carcinogen with carcinogenic activity. AalphaC is an important biomarker in tobacco smoke and is associated with tobacco smoke exposure. Urinary concentrations of AalphaC are significantly higher in dedicated smokers than in non-smokers, indicating its importance in monitoring tobacco exposure. AalphaC levels increase significantly with increasing serum nicotine levels, indicating its close relationship with tobacco use. In addition, consuming high-temperature cooked beef significantly increases the amount of AalphaC in urine, while consuming vegetables is associated with a decrease in AalphaC concentrations. Smoking half a pack of cigarettes is associated with a significant increase in the amount of AalphaC, which further confirms the biological activity of AalphaC and its association with dietary habits .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-W011824
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-O-Methyluridine is a modified nucleoside that can be found in T. thermophile tRNA. 2’-O-Methyluridine can be incorporated into siRNA targeting the gene encoding apolipoprotein B, which decreases ApoB protein levels in HepG2 and prevents IFN-α production in isolated human PBMCs. 2’-O-Methyluridine level in serum is decreased in patients with breast cancer .
|
-
- HY-160552
-
|
|
|
Cationic Lipids
|
|
244cis, a piperazine-containing ionizable cationic lipid, has been used to generate lipid nanoparticles (LNPs). LNPs containing 244cis and coated with mRNA reporter gene were specifically accumulated in mouse lungs compared with LNPs containing SM-102. Induces a decrease in serum chemokine (C-C motif) ligand 2 (CCL2) levels .
|
-
- HY-134508
-
|
|
|
Phospholipids
|
|
C24-Ceramide is an orally active competitive binding agonist of PIP4K2C (mTOR complex regulator), thereby activating the mTOR signaling pathway. At the same time, C24-Ceramide changes the membrane morphology by inducing the formation of a partially interlocked gel phase in the phospholipid bilayer. C24-Ceramide can promote the proliferation and migration of keratinocytes to accelerate skin wound healing and drive the proliferation and metastasis of gallbladder cancer cells. The level of C24-Ceramide in serum can be used as a diagnostic marker for gallbladder cancer .
|
-
- HY-W587488
-
|
3′-AMP
|
|
Nucleotide Analogs
Adenine Nucleotide
|
|
Adenosine 3’-monophosphate (3’-AMP) is a nucleotide. Adenosine 3’-monophosphate is a cyclic AMP production agonist. Adenosine 3’-monophosphate increases cyclic AMP levels concentration-dependently in NG108-15 cells. Adenosine 3’-monophosphate can be used in the determination of acid phosphatase activity of human serum, which is estabilished as a laboratory procedure in the diagnosis of prostate cancer, metastatic mammary cancer and Gaucher’s disease. Adenosine 3’-monophosphate inhibits human aortic and coronary vascular smooth muscle cell proliferation via A2B receptors .
|
-
- HY-145547
-
|
14:0 Lyso PE; 1-Myristoyl-2-hydroxy-sn-glycero-3-PE; 1-Tetradecanoyl-sn-glycero-3-phosphoethanolamine
|
|
Phospholipids
|
|
1-Myristoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine (14:0 Lyso PE) is a lysophospholipid with a phosphoethanolamine head and a myristoyl tail. The free amine group can conjugate with NHS active ester or coupled with carboxylic acid in the presence of a coupling agent. It also induces transient increases in intracellular calcium in PC12 cells . Serum levels of 1-Myristoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine are elevated in patients with malignant breast cancer compared to healthy controls .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
